This research was supported by the NIH (GM71772 and GM65933 to T.M.K.; GM071688 and GM071688-03S1 to E.M.D.L.C.). T.M.K. is a Scholar of the Leukemia and Lymphoma Society. H.F.C. was supported by an NIH predoctoral fellowship (F31 DC009143) and, in part, by a grant from the Yale Institute for Quantum Engineering (awarded to E.M.D.L.C.). E.M.D.L.C. is an American Heart Association Established Investigator (0940075N) and an NSF CAREER Award recipient (MCB-0546353). We thank Dr. Benjamin H. Kwok and Dr. Alexander Kelly for providing us with recombinant PLK1 and Aurora kinase.
A Myosin V Inhibitor Based on Privileged Chemical Scaffolds†
Version of Record online: 28 SEP 2010
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 49, Issue 45, pages 8484–8488, November 2, 2010
How to Cite
Islam, K., Chin, H. F., Olivares, A. O., Saunders, L. P., De La Cruz, E. M. and Kapoor, T. M. (2010), A Myosin V Inhibitor Based on Privileged Chemical Scaffolds. Angew. Chem. Int. Ed., 49: 8484–8488. doi: 10.1002/anie.201004026
- Issue online: 29 OCT 2010
- Version of Record online: 28 SEP 2010
- Manuscript Revised: 5 AUG 2010
- Manuscript Received: 1 JUL 2010
- NIH. Grant Numbers: GM71772, GM65933, GM071688, GM071688-03S1
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.